News & Media
IGC PHARMA Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s Agitation
Both the primary and secondary objectives aim to evaluate the efficacy of IGC-AD1 in reducing agitation as assessed by the CMAI at week 2 and week 6 respectively.
IGC Pharma Releases Positive Interim Analysis Of Its Ongoing Phase 2 Trial In Alzheimer’s Research
By: Faith Ashmore Benzinga Staff Writer As of 2023, the estimated number of Americans living with Alzheimer’s disease was 6.7 million. However, a lesser-known subsection of Alzheimer’s is Agitation in dementia from
IGC Pharma Advances in Alzheimer’s Research from Pre-clinical Studies to Phase Two Trials with its Novel Therapy Candidate IGC-AD1
By: Faith Ashmore Benzinga Staff Writer Alzheimer’s disease, a progressive neurological disorder, affects around 24 million individuals worldwide. It is characterized by memory loss, cognitive decline and behavioral changes. The impact
Alzheimer´s awareness Day 2023
On this day let’s talk about the power of education and how it can bring hope and understanding to patients, caregivers, and families affected by this condition.
IGC powers Alzheimer’s and cannabis research with AI
IGC will aim for FDA fast-track designation after a Phase II trial investigating IGC-AD1 with AD patients concludes in Q1 2024.
Unlocking the Future of Dementia Science: Discover our Topics for the AAIC 2023
Discover cutting-edge dementia science at AAIC Amsterdam. Breakthroughs and connections thrive as leading experts unite at the world’s largest conference on Alzheimer’s research.